Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst David S Macdonald reaffirmed a Hold rating on Quest Diagnostics (DGX) with a $250 price target. While Robert W. Baird also issued a Hold, Barclays maintained a Buy rating on the stock today.
Truist Financial analyst David S Macdonald maintained a Hold rating on Quest Diagnostics today and set a price target of $250.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
S Macdonald covers the Healthcare sector, focusing on stocks such as Centene, CVS Health, and Molina Healthcare. According to TipRanks, S Macdonald has an average return of 12.4% and a 62.12% success rate on recommended stocks.
In addition to Truist Financial, Quest Diagnostics also received a Hold from Robert W. Baird’s Eric Coldwell in a report issued today. However, on the same day, Barclays maintained a Buy rating on Quest Diagnostics (NYSE: DGX).